Novel immunosuppressive agents in kidney transplantation

Clinical Nephrology

Volumn 73, Issue 5, 2010, Pages 333-343

  Cooper, J E ^a   Wiseman, A C ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Clinical trials review; Immunosuppression; Kidney transplant

Indexed keywords

4 [N [1 (2 CYANO 1 OXOETHYL) 4 METHYL 3 PIPERIDINYL] N METHYLAMINO]PYRROLO[2,3 D]PYRIMIDINE; ABATACEPT; ALEFACEPT; BASILIXIMAB; BELATACEPT; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN A; EFALIZUMAB; EVEROLIMUS; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; ISA 247; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PREDNISONE; RAPAMYCIN; SOTRASTAURIN; STEROID; TACROLIMUS; UNCLASSIFIED DRUG; VOCLOSPORIN;

ALLOIMMUNITY; ANEMIA; ANTIGEN PRESENTING CELL; CARDIAC GRAFT REJECTION; CLINICAL PROTOCOL; CLINICAL TRIAL; CYTOKINE PRODUCTION; CYTOMEGALOVIRUS INFECTION; DOSE RESPONSE; DRUG APPROVAL; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; GRAFT REJECTION; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HUMAN; HYPERCHOLESTEROLEMIA; INFECTION; KIDNEY DISEASE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; LYMPHOCELE; LYMPHOCYTIC INFILTRATION; LYMPHOPROLIFERATIVE DISEASE; MAINTENANCE THERAPY; NONHUMAN; PROTEINURIA; PSORIASIS; PSORIASIS VULGARIS; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION;

EID: 77951661580     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CNP73333     Document Type: Review

References (73)

1. Asao H, Okuyama C, Kumaki S, Ishii N, Tsuchiya S, Foster D, Sugamura K. Cutting edge: the common gamma-chain is an indispensable subunit of the IL-21 receptor complex. JImmunol. 2001; 167: 1-5. (Pubitemid 32567752)
2. Aspeslet L, Freitag D, Trepanier D, Abel M, Naicker S, Kneteman N, Foster R, Yatscoff R. ISA(TX)247: a novel calcineurin inhibitor. Transplant Proc. 2001; 33: 1048-1051.
3. Baier G. The PKC gene module: molecular biosystematics to resolve its T cell functions. Immunol Rev. 2003; 192: 64-79. (Pubitemid 36613324)
4. Bigaud M, Riesen S, Menninger K, Barbet I, Jean C, Beerli C, Audet M, Blancher A, Heusser C, Wagner J, Morris RE. NVP-AEB071 (AEB), a novel oral inhibitor of early T cell activation, prolongs the survival of non-human primate (NHP) kidney allografts when used as monotherapy or at non-effective doses combined with a non-effective dose of cyclosporine (CsA) (abstract #546). Am J Transplant. 2006; 6: 250.
5. Borie DC, Larson MJ, Flores MG, Campbell A, Rousvoal G, Zhang S, Higgins JP, Ball DJ, Kudlacz EM, Brissette WH, Elliott EA, Reitz BA, Changelian PS. 690,550 with mycophenolate mofetil to prevent kidney allograft rejection in nonhuman primates. Transplantation. 2005; 80: 1756-1764.
6. Borie DC, Changelian PS, Larson MJ, Si MS, Paniagua R, Higgins JP, Holm B, Campbell A, Lau M, Zhang S, Flores MG, Rousvoal G, Hawkins J, Ball DA, Kudlacz EM, Brissette WH, Elliott EA, Reitz BA, Morris RE. Immunosuppression by the JAK3 inhibitor CP-690,550 delays rejection and significantly prolongs kidney allograft survival in nonhuman primates. Transplantation. 2005; 79: 791-801. (Pubitemid 40546198)
7. Buckley RH. The multiple causes of human SCID. J Clin Invest. 2004; 114: 1409-1411.
8. Budde K, Becker T, Asderakis A, Pietruck F, Grinyo JM, Rigotti P, Dantal J, Ng J, Barten MJ, Weber M. AEB071, a Novel Protein Kinase C-Inhibitor: First Clinical Results of an AEB071 Plus Tacrolimus Regimen in Renal Transplant Recipients (abstract #391). American Transplant Congress 2009 abstracts. 2009.
9. Busque S, Leventhal J, Brennan DC, Steinberg S, Klintmalm G, Shah T, Mulgaonkar S, Bromberg JS, Vincenti F, Hariharan S, Slakey D, Peddi VR, Fisher RA, Lawendy N,Wang C, Chan G. Calcineurin-inhibitor-free immunosuppression based on the JAK inhibitor CP-690,550: a pilot study in de novo kidney allograft recipients. Am J Transplant. 2009; 9: 1936-1945.
10. Chan L, Gaston R, Hariharan S. Evolution of immunosuppression and continued importance of acute rejection in renal transplantation. Am J Kidney Dis. 2001; 38: 2-9. (Pubitemid 34184668)
11. Changelian PS, Flanagan ME, Ball DJ, Kent CR, Magnuson KS, Martin WH, Rizzuti BJ, Sawyer PS, Perry BD, Brissette WH, McCurdy SP, Kudlacz EM, Conklyn MJ, Elliott EA, Koslov ER, Fisher MB, Strelevitz TJ, Yoon K, Whipple DA, Sun J, Munchhof MJ, Doty JL, Casavant JM, Blumenkopf TA, Hines M, Brown MF, Lillie BM, Subramanyam C, Shang-Poa C, Milici AJ, Beckius GE, Moyer JD, Su C, Woodworth TG, Gaweco AS, Beals CR, Littman BH, Fisher DA, Smith JF, Zagouras P, Magna HA, Saltarelli MJ, Johnson KS, Nelms LF, Des Etages SG, Hayes LS, Kawabata TT, Finco-Kent D, Baker DL, Larson M, Si MS, Paniagua R, Higgins J, Holm B, Reitz B, Zhou YJ, Morris RE, O'Shea JJ, Borie DC. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science. 2003; 302: 875-878. (Pubitemid 37339629)
12. Clarkson MR, Sayegh MH. T-cell costimulatory pathways in allograft rejection and tolerance. Transplantation. 2005; 80: 555-563. (Pubitemid 41377737)
13. Darnell JE Jr, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science. 1994; 264: 1415-1421.
14. Dhanireddy K, Zhang X, LeopardiF, Johnson L, Kirk A. Alefacept (LFA-3-Ig), portal venous donor specific transfusion, and sirolimus prolong renal allograft survival in non-human primates (abstract #1627).The 2006 World Transplant Congress. 2006.
15. Durrbach A, Medina-Pestana JD, Vanrenterghem Y, Vincenti F, Florman S, Block AJ, Garg P, Sen K, Grinyo J. Primary Outcomes from a Randomized, Phase III Study of Belatacept vs Cyclosporine in ECD Kidney Transplants (BENEFIT-EXT Study) (abstract #27). American Transplant Congress 2009 abstracts. 2009.
16. Ekberg H, Tedesco-Silva H, Demirbas A, Vitko S, Nashan B, Gurkan A, Margreiter R, Hugo C, Grinyo JM, Frei U, Vanrenterghem Y, Daloze P, Halloran PF. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med. 2007; 357: 2562-2575. (Pubitemid 350294223)
17. Evenou JP, Wagner J, Zenke G, Brinkmann V, Wagner K, Kovarik J, Welzenbach KA, Weitz-Schmidt G, Guntermann C, Towbin H, Cottens S, Kaminski S, Letschka T, Lutz-Nicoladoni C, Gruber T, Hermann-Kleiter N, Thuille N, Baier G. The potent protein kinase C-selective inhibitor AEB071 (sotrastaurin) represents a new class of immunosuppressive agents affecting early T-cell activation. J Pharmacol Exp Ther. 2009; 330: 792-801.
18. Flechner SM, Goldfarb D, Solez K, Modlin CS, Mastroianni B, Savas K, Babineau D, Kurian S, Salomon D, Novick AC, Cook DJ. Kidney transplantation with sirolimus and mycophenolate mofetil-based immunosuppression: 5-year results of a randomized prospective trial compared to calcineurin inhibitor drugs.Transplantation. 2007; 83: 883-892.
19. Friman S, Banas B, Chan L, Mulgaonkar S, Nashan B, Soergel M,VincentiF,Wissing KM,Witte S,Woodle ES. AEB071, a Novel Protein Kinase C-Inhibitor: Evaluation of an AEB071 PlusMycophenolate Regimen in Renal Transplant Recipients (abstract #458). American Transplant Congress 2009 abstracts. 2009.
20. Gaber AO, Mulgaonkar S, Gaston R, Jevnikar A, Meier-Kriesche HU. ISA247: A Phase IIB Multicenter, Open Label, Concentration-Controlled Trial in de novo Renal Transplantation (abstract #LB06). Am J Transplant. 2008; 8: 336.
21. Gregory CR, Kyles AE, Bernsteen L, Wagner GS, Tarantal AF, Christe KL, Brignolo L, Spinner A, Griffey SM, Paniagua RT, Hubble RW, Borie DC, Morris RE. Compared with cyclosporine, ISATX247 significantly prolongs renal-allograft survival in a nonhuman primate model. Transplantation. 2004; 78: 681-685.
22. Gudmundsdottir H, Turka LA. Tcell costimulatory blockade: new therapies for transplant rejection. J Am Soc Nephrol. 1999; 10: 1356-1365.
23. Hariharan S, Johnson CP, Bresnahan BA, Taranto SE, McIntosh MJ, Stablein D. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med. 2000; 342: 605-612.
24. Jenkins MK, Taylor PS, Norton SD, Urdahl KB. CD28 delivers a costimulatory signal involved in antigen-specific IL-2 production by human T cells. J Immunol. 1991; 147: 2461-2466.
25. Johnson RW, Kreis H, Oberbauer R, Brattstrom C, Claesson K, Eris J. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation. 2001; 72: 777-786. (Pubitemid 32879845)
26. Kaplon RJ, Hochman PS, Michler RE, Kwiatkowski PA, Edwards NM, Berger CL, Xu H, Meier W, Wallner BP, Chisholm P, Marboe CC. Short course single agent therapy with an LFA-3-IgG1 fusion protein prolongs primate cardiac allograft survival. Transplantation. 1996; 61: 356-363. (Pubitemid 26067904)
27. Kirk AD, Harlan DM, Armstrong NN, Davis TA, Dong Y, Gray GS, Hong X, Thomas D, Fechner JH Jr, Knechtle SJ. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci USA. 1997; 94: 8789-8794. (Pubitemid 27335118)
28. Kreis H, Oberbauer R, Campistol JM, Mathew T, Daloze P, Schena FP, Burke JT, Brault Y, Gioud-Paquet M, Scarola JA, Neylan JF. Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal. J Am Soc Nephrol. 2004; 15: 809-817. (Pubitemid 38294812)
29. Krueger GG, Ellis CN. Alefacept therapy produces remission for patients with chronic plaque psoriasis. Br J Dermatol. 2003; 148: 784-788.
30. Larsen CP, Pearson TC, Adams AB, Tso P, Shirasugi N, Strobertm E, Anderson D, Cowan S, Price K, Naemura J, Emswiler J, Greene J, Turk LA, Bajorath J, Townsend R, Hagerty D, Linsley PS, Peach RJ. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant. 2005; 5: 443-453. (Pubitemid 40313335)
31. Larson TS, Dean PG, Stegall MD, Griffin MD, Textor SC, Schwab TR, Gloor JM, Cosio FG, Lund WJ, Kremers WK, Nyberg SL, Ishitani MB, Prieto M, Velosa JA. Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus. Am J Transplant. 2006; 6: 514-522. (Pubitemid 43382137)
32. Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell costimulation. Annu Rev Immunol. 1996; 14: 233-258.
33. Macchi P, Villa A, Giliani S, Sacco MG, Frattini A, Porta F, Ugazio AG, Johnston JA, Candotti F, O'Shea JJ et al. Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID). Nature. 1995; 377: 65-68.
34. Majeau GR, Meier W, Jimmo B, Kioussis D, Hochman PS. Mechanism of lymphocyte function-associated molecule 3-Ig fusion proteins inhibition of T cell responses. Structure/function analysis in vitro and in human CD2 transgenicmice. J Immunol. 1994; 152: 2753-2767. (Pubitemid 24097971)
35. Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant. 2004; 4: 378-383. (Pubitemid 38282293)
36. Miller GT, Hochman PS, Meier W, Tizard R, Bixler SA, Rosa MD, Wallner BP. Specific interaction of lymphocyte function-associated antigen 3 with CD2can inhibit Tcell responses. J Exp Med. 1993; 178: 211-222. (Pubitemid 23173256)
37. Miyazaki T, Kawahara A, Fujii H, Nakagawa Y, Minami Y, Liu ZJ, Oishi I, Silvennoinen O, Witthuhn BA, Ihle JN et al. Functional activation of Jak1 and Jak3 by selective association with IL-2 receptor subunits. Science. 1994; 266: 1045-1047. (Pubitemid 24373722)
38. Moreland LW, Alten R, Van den Bosch F, Appelboom T, Leon M, Emery P, Cohen S, Luggen M, Shergy W, Nuamah I, Becker JC. Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dosefinding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eightyfive days after the first infusion. Arthritis Rheum. 2002; 46: 1470-1479. (Pubitemid 34620192)
39. Mulay AV, Cockfield S, Stryker R, Fergusson D, Knoll GA. Conversion from calcineurin inhibitors to sirolimus for chronic renal allograft dysfunction: a systematic review of the evidence. Transplantation. 2006; 82: 1153-1162. (Pubitemid 44748017)
40. Mulebacher F, Larsen C, Agarwal M, Vincenti F. Long-term safety of belatacept: 6 year results of a Phase II study (abstract #621). XXII International Congress of the Transplant Society: http://tc08proceedings. cmsaustralasia.com/Abstracts.pdf#page= 218. 2008; 218.
41. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR. The natural history of chronic allograft nephropathy. N Engl J Med. 2003; 349: 2326-2333.
42. Nicolls MR, Gill RG. LFA-1 (CD11a) as a therapeutic target. Am J Transplant. 2006; 6: 27-36.
43. Noguchi M, Yi H, Rosenblatt HM, Filipovich AH, Adelstein S, Modi WS, McBride OW, Leonard WJ. Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans. Cell. 1993; 73: 147-157. (Pubitemid 23115456)
44. Oberbauer R, Segoloni G, Campistol JM, Kreis H, Mota A, Lawen J, Russ G, Grinyo JM, Stallone G, Hartmann A, Pinto JR, Chapman J, Burke JT, Brault Y, Neylan JF. Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48months after transplantation. Transpl Int. 2005; 18: 22-28. (Pubitemid 41742941)
45. Ostermann G, Weber KS, Zernecke A, Schroder A, Weber C. JAM-1 is a ligand of the beta(2) integrin LFA-1 involved in transendothelialmigration of leukocytes. Nat Immunol. 2002; 3: 151-158.
46. Papp K, Bissonnette R, Rosoph L, Wasel N, Lynde CW, Searles G, Shear NH, Huizinga RB, Maksymowych WP. Efficacy of ISA247 in plaque psoriasis: a randomised, multicentre, double-blind, placebo-controlled Phase III study. Lancet. 2008; 371: 1337-1342. (Pubitemid 351522314)
47. Parganas E, Wang D, Stravopodis D, Topham DJ, Marine JC, Teglund S, Vanin EF, Bodner S, Colamonici OR, van Deursen JM, Grosveld G, Ihle JN. Jak2 is essential for signaling through a variety of cytokine receptors. Cell. 1998; 93: 385-395. (Pubitemid 28232083)
48. Pearson TC, Patel A, Scandling J, Shidban H, Weir M, Patel D. Efficacy and Safety of Mycophenolate Mofetil (MMF)/Sirolimus (SRL) Maintenance Therapy after Calcineurin Inhibitor (CNI) Withdrawal in Renal Transplant Recipients: Final Results of the Spare-the-Nephron (STN) Trial (abstract #129). Am J Transplant. 2008; 8: 213.
49. Poston RS, Robbins RC, Chan B, Simms P, Presta L, Jardieu P, Morris RE. Effects of humanized mono-clonal antibody to rhesus CD11a in rhesus monkey cardiac allograft recipients. Transplantation. 2000; 69: 2005-2013. (Pubitemid 30395025)
50. Reiser H, Stadecker MJ. Costimulatory B7 molecules in the pathogenesis of infectious and autoimmune diseases. N Engl J Med. 1996; 335: 1369-1377.
51. Schena FP, Pascoe MD, Alberu J, del Carmen Rial M, Oberbauer R, Brennan DC, Campistol JM, Racusen L, Polinsky MS, Goldberg-Alberts R, Li H, Scarola J, Neylan JF. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation. 2009; 87: 233-242.
52. Schuurman HJ, Cottens S, Fuchs S, Joergensen J, Meerloo T, Sedrani R, Tanner M, Zenke G, Schuler W.SDZ RAD, a new rapamycin derivative: synergism with cyclosporine. Transplantation. 1997; 64: 32-35.
53. Shapira MY, Abdul-Hai A, Resnick IB, Bitan M, Tsirigotis P, Aker M, Gesundheit B, Slavin S, Or R. Alefacept treatment for refractory chronic extensive GVHD. Bone Marrow Transplant. 2009; 43: 339-343.
54. Skvara H, Dawid M, Kleyn E, Wolff B, Meingassner JG, Knight H, Dumortier T, Kopp T, Fallahi N, Stary G, Burkhart C, Grenet O, Wagner J, Hijazi Y, Morris RE, McGeown C, Rordorf C, Griffiths CE, StinglG, Jung T. The PKC inhibitor AEB071 may be a therapeutic option for psoriasis. J Clin Invest. 2008; 118: 3151-3159.
55. Slade A, Agyemang A, Sieberling M, Schmouder R. NVP-AEB071:Human Pharmacodynamics in Combination with Mycophenolic Acid (abstract #396). Am J Transplant. 2006; 6: 199.
56. Stalder M, Birsan T, Hubble RW, Paniagua RT, Morris RE. In vivo evaluation of the novel calcineurin inhibitor ISATX247 in non-human primates. J Heart Lung Transplant. 2003; 22: 1343-1352.
57. Stepkowski SM, Kirken RA. Janus tyrosine kinases and signal transducers and activators of transcription regulate critical functions of T cells in allograft rejection and transplantation tolerance. Transplantation. 2006; 82: 295-303.
58. Sultan P, Schechner JS, McNiff JM, Hochman PS, Hughes CC, Lorber MI, Askenase PW, Pober JS. Blockade of CD2-LFA-3 interactions protects human skin allografts in immunodeficient mouse/human chimeras. Nat Biotechnol. 1997; 15: 759-762. (Pubitemid 27329478)
59. Tan SL, Parker PJ. Emerging and diverse roles of protein kinase C in immune cell signalling. Biochem J. 2003; 376: 545-552.
60. Tedesco-Silva H Jr, Vitko S, Pascual J, Eris J, Magee JC, Whelchel J, Civati G, Campbell S, Alves-Filho G, Bourbigot B, Garcia VD, Leone J, Esmeraldo R, Rigotti P, Cambi V,Haas T. 12-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients. Transpl Int. 2007; 20: 27-36. (Pubitemid 44950360)
61. van Gurp E, Weimar W, Gaston R, Brennan D, Mendez R, Pirsch J, Swan S, PescovitzMD, Ni G, Wang C, Krishnaswami S, Chow V, Chan G. Phase I dose-escalation study of CP-690 550 in stable renal allograft recipients: preliminary findings of safety, tolerability, effects on lymphocyte subsets and pharmacokinetics. Am J Transplant. 2008; 8: 1711-1718.
62. van Gurp EA, Schoordijk-Verschoor W, Klepper M, Korevaar SS, Chan G, Weimar W, Baan CC. The effect of the JAK inhibitor CP-690,550 on peripheral immune parameters in stable kidney allograft patients. Transplantation. 2009; 87: 79-86.
63. Velotta JB, Deuse T, Haddad M, Masuda E, Park G, Carroll D, Taylor V, Robbins RC, Schrepfer S. A novel JAK3 inhibitor, R348, attenuates chronic airway allograft rejection. Transplantation. 2009; 87: 653-659.
64. Vincenti F, Kirk AD. What's next in the pipeline. Am J Transplant. 2008; 8: 1972-1981.
65. Vincenti F, Mendez R, Pescovitz M, Rajagopalan PR, Wilkinson AH, Butt K, Laskow D, Slakey DP, Lorber MI, Garg JP, Garovoy M. A Phase I/II randomized open-label multicenter trial of efalizumab, a humanized anti-CD11a, anti-LFA-1 in renal transplantation. Am J Transplant. 2007; 7: 1770-1777. (Pubitemid 46905435)
66. Vincenti F, Larsen C, Durrbach A, Wekerle T, Nashan B, Blancho G, Lang P, Grinyo J, Halloran PF, Solez K, Hagerty D, Levy E, Zhou W, Natarajan K, Charpentier B. Costimulation blockade with belatacept in renal transplantation. N Engl J Med. 2005; 353: 770-781. (Pubitemid 41215486)
67. Vincenti F, Charpentier B, Medina-Pestana JD, Rostaing L, Vanrenterghem Y, Di Russo GB, Garg P, Lin CS, Larsen C. Primary Outcomes from a Randomized, Phase III Study of Belatacept vs Cyclosporine in Kidney Transplant Recipients (BENEFIT Study) (abstract #4). American Transplant Congress 2009 abstracts. 2009.
68. Vitko S, Margreiter R, Weimar W, Dantal J, Kuypers D, Winkler M, Oyen O, Viljoen HG, Filiptsev P, Sadek S, Li Y, Cretin N, Budde K. Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients. Am J Transplant. 2005; 5: 2521-2530. (Pubitemid 43919438)
69. Wagner J, Zenke G, Brinkmann V, Pally C, Bigaud M, Burkhart C, Cottens S, Jung T, Rordorf C, Morris RE. The first-in-class oral protein kinase C (PKC) inhibitor NVP-AEB071 (AEB) prolongs renal allograft survival in non-human primates (NHP) and suppresses lymphocyte proliferation at safe exposures in human proof of concept sutdies (abstract #57). Am J Transplant. 2006; 6: 86.
70. Walunas TL, Bakker CY, Bluestone JA. CTLA-4 ligation blocks CD28-dependent T cell activation. J Exp Med. 1996; 183: 2541-2550.
71. Wange RL, Samelson LE. Complex complexes: signaling at the TCR. Immunity. 1996; 5: 197-205.
72. Weaver TA, Charafeddine AH, Agarwal A, Turner AP, Russell M, Leopardi FV, Kampen RL, Stempora L, Song M, Larsen CP, Kirk AD. Alefacept promotes co-stimulation blockade based allograft survival in nonhuman primates. Nat Med. 2009; 15: 746-749.
73. Werther WA, Gonzalez TN, O'Connor SJ, McCabe S, Chan B, Hotaling T, Champe M, Fox JA, Jardieu PM, Berman PW, Presta LG. Humanization of an anti-lymphocyte function-associated antigen (LFA)-1 monoclonal antibody and reengineering of the humanized antibody for binding to rhesus LFA-1. J Immunol. 1996; 157: 4986-4995. [74] Witthuhn BA, Silvennoinen O, Miura O, Lai KS, Cwik C, Liu ET, Ihle JN. Involvement of the Jak-3 Janus kinase in signalling by interleukins 2 and 4 in lymphoid and myeloid cells. Nature. 1994; 370: 153-157. (Pubitemid 126449577)